Sugiura H, Sato K, Yamamura S, Nagasaka T, Takahashi M, Katagiri H
Department of Orthopaedic Surgery and Pathology, Nagoya University School of Medicine, Japan.
Arch Orthop Trauma Surg. 1995;114(5):248-52. doi: 10.1007/BF00452080.
To determine the value of proliferating cell nuclear antigen (PCNA) staining as a prognostic indicator in soft-tissue malignant fibrous histiocytoma (MFH), we studied 27 patients who underwent resection including an adequately wide margin but without chemotherapy. The survival rate of patients with a lesion in which less than 70% of the cells was positively stained was significantly higher (P < 0.01) than of those with more than 70% positive staining. Twenty-two patients (81.5%) evidenced disease-free survival (mean follow-up period 4.6 years), 1 patient was alive with disease, and 4 (14.8%) died of the disease with lung or lymph node metastasis. In all 4 patients who died, PCNA staining was over 70% positive. In 2 of them, an increase in the number of PCNA-positive cells was observed after repeated recurrence. We conclude that PCNA is a useful prognostic indicator which provides a quantitative measure of the grade of malignancy in MFH patients who receive operative treatment without chemotherapy.
为了确定增殖细胞核抗原(PCNA)染色作为软组织恶性纤维组织细胞瘤(MFH)预后指标的价值,我们研究了27例接受手术切除(切缘足够宽但未接受化疗)的患者。细胞阳性染色少于70%的患者生存率显著高于(P<0.01)阳性染色超过70%的患者。22例患者(81.5%)无病生存(平均随访期4.6年),1例患者带瘤生存,4例(14.8%)死于伴有肺或淋巴结转移的疾病。在所有4例死亡患者中,PCNA染色阳性率超过70%。其中2例在反复复发后观察到PCNA阳性细胞数量增加。我们得出结论,PCNA是一个有用的预后指标,它为未接受化疗的手术治疗MFH患者的恶性程度提供了一种定量测量方法。